السهم نازل عليه خبر
فيه شي زين وفيه شي شين
اليكم الخبر
WATERTOWN, Mass. (Dow Jones)-- V.I. Technologies Inc. (VITX, news) raised its private placement value to $10 million from $6.6 million, with net proceeds going to the phase III development of its lead product.
In a press release Friday, the biotechnology company that develops products to improve the safety of blood supply, said it will sell an additional 2.96 million shares of common stock to institutional investors at $1.15 a share, for an incremental sum of $3.4 million.
A spokesman couldn't be reached for comment.
The company recently completed a $4 million private placement in December.
For third quarter ended Sept. 27, Vitex recorded a net loss of $6.7 million, or 16 cents a share, on revenue of $105 million. Research and development costs were $5.79 million.
The weighted-average number of shares was 40.9 million during the latest quarter, almost doubling the count of 22.8 million a year earlier.
V.I. Tech said the investors will also receive a five-month option to purchase 739,130 additional shares at $1.15 a share and four-year warrants to buy 1.18 million shares at $1.75 a share.
The company's stock recorded a 52-week high of $3.98 a share in June and a low of 55 cents in November.
V.I. Technologies' shares were recently traded on Nasdaq at $1.47, down 9 cents, or 5.7%.
The company's lead product, Inactine Pathogen Reduction System, is designed to inactivate a wide range of viruses, bacteria, and parasites, and removes prion proteins while preserving the therapeutic properties of red blood cells.
خذ راحتك وقول اللي تبي تقوله